

## **Unresectable or Metastatic Gastrointestinal Stromal Tumors: Pharmacist Implications on the Evolving Treatment Landscape**

### **Selected References**

- Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2020;21(7):923-934.
- Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018;29(Suppl 4):iv68-iv78.
- Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *Lancet Oncol.* 2020;21(7):935-946.
- Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. *J Hematol Oncol.* 2021;14(1):2.
- Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. *Ther Adv Med Oncol.* 2021;13:1-12.
- Mazzocca A, Napolitano A, Silletta M, et al. New frontiers in the medical management of gastrointestinal stromal tumours. *Ther Adv Med Oncol.* 2019;11:1-13.
- von Mehren M, Joensuu H. Gastrointestinal stromal tumors. *J Clin Oncol.* 2018;36(2):136-143.
- Wang AA, Tapia C, Bhanji Y, et al. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation. *J Oncol Pharm Pract.* 2020;26(2):279-285.